Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LY2603618 + STP-B |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY2603618 | LY-2603618|Rabusertib | CHK1 Inhibitor 18 | Rabusertib (LY2603618) is a small molecule that inhibits CHK1, which may lead to disruption of DNA synthesis, early mitosis, and apoptosis, and may increase tumor cell sensitivity to chemotherapeutics (PMID: 24114124, PMID: 28625637). | |
STP-B | STP-B inhibits CTPS1, which results in induction of DNA double-strand breaks, cell cycle arrest, and apoptosis, and potentially inhibits tumor growth (PMID: 37898670). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|